Yu Fujimura

Mr. Yu Fujimura


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2026 in Cancers
Verified
Journal Article
Open access
PDF file
YFYu Fujimura
Yu Fujimura
NKNaohisa Kuriyama
Naohisa Kuriyama
YSYuki Segi
Yuki Segi
HKHaruna Komatsubara
Haruna Komatsubara
KGKazuyuki Gyoten
Kazuyuki Gyoten
SMShugo Mizuno
Shugo Mizuno
Background/Objectives: Early recurrence (ER) after curative-intent resection of perihilar cholangiocarcinoma (PHC) is associated with poor prognosis. However, simple preoperative predictors remain insufficiently defined. This study aimed to identify preoperative factors associated with ER and explore a risk classification. Methods: We retrospectively analyzed 108 patients who underwent curative-intent resection for PHC at a single institution between 2007 and 2023. ER was defined as recurrence within 1 year after surgery. Cox proportional hazards regression was used to identify associated factors. Results: ER occurred in 24 patients (22.2%). Multivariable analysis identified younger age (hazard ratio [HR] = 0.942), higher carcinoembryonic antigen (CEA; HR = 1.115), higher carbohydrate antigen 19-9 (CA19-9; HR = 1.001), and higher neutrophil-to-lymphocyte ratio (NLR; HR = 1.404) as factors associated with ER. In an exploratory classification, one point was assigned for age < 61 years, CEA ≥ 5.4 ng/mL, CA19-9 ≥ 89.4 U/mL, and NLR ≥ 2.037. Among 105 patients with complete data, the estimated 1-year recurrence rate was 70.0% in patients with 3–4 points (n = 10), versus 17.4% in those with 0–2 points (n = 95; p < 0.001). Bootstrap analysis suggested optimism in the score’s apparent discrimination when cutoff optimization was considered (optimism-corrected C-index, 0.668). Conclusions: Age, CEA, CA19-9, and NLR were associated with ER after PHC resection. The exploratory classification requires external validation before clinical use.